CHIEF EXECUTIVE OFFICER
+1 949 294-0806 firstname.lastname@example.org
Kira has been appointed Chief Executive Officer for Reapplix in May 2021. Prior to joining Reapplix, Kira successfully introduced new wound care growth platforms as Head of Global Marketing and a member of the global management board at Urgo Medical. Under her leadership, Urgo Medical grew to become the second-largest advanced wound care company in Europe. Kira has over a decade of experience in various marketing roles in the medical device and biologics space both at Johnson & Johnson and Allergan in the US and Europe. In addition to healthcare, she has experience working in financial services at JP Morgan Chase.
Kira has an MBA from Harvard Business School and a BA in Economics and International Relations from Brown University.
CHIEF OPERATING OFFICER
+45 25 44 83 57 email@example.com
Carsten brings extensive experience from working in international organisations within Pharmaceutical, Medical Device and Biotech. He has an Executive MBA and a degree in Chemical Engineering and has for more than 25 years been working within Manufacturing and Supply Chain for Novo Nordisk, Dako, Exiqon and Ferrosan Medical Devices. Carsten joined Reapplix October 2021.
CHIEF SCIENTIFIC OFFICER
+45 26 71 74 47 firstname.lastname@example.org
Rasmus has a MSc. in biology and immunology from Copenhagen University and a graduate certificate in Biodesign from Stanford University. He is highly experienced in working with the development of in-vitro assays for the characterization of growth factor containing products. He analyzed chronic wound fluid by microarray technology at Copenhagen Wound Healing Center and Van Andel Research Institute, MI, USA. He is an experienced entrepreneur and co-founded RAM Biotech Aps in 2001 prior to his involvement with Reapplix. His exceptional skills have been a key factor in characterizing LeucoPatch® – now named 3C Patch® – and guiding the product development, clinical and product positioning activities. He is a founder of Reapplix.
MORTEN HAVE RASMUSSEN
CHIEF FINANCIAL OFFICER
+45 253 64 74 47 email@example.com
Morten is an executive with background in finance and audit. Professional experience includes 4 years as audit manager at KPMG C. Jespersen and more than 12 years group finance experience from companies listed on Nasdaq Copenhagen. In the period 2011-2018 he held positions as Director of Finance for the life science companies Exiqon and QIAGEN. Morten has a M.Sc in Business Economics & Auditing (Cand. Merc. Aud.) from Copenhagen Business School. Morten joined Reapplix in February 2018.
VP MARKETING & STRATEGY
+1 631-835-2403 firstname.lastname@example.org
Cory brings over 15 years combined experience in Healthcare, Medical Device and Financial Sales. She has extensive commercial leadership and marketing experience in various roles in advanced wound and diabetes care in startups as well as multinationals. Prior to joining Reapplix, Cory was the Head of US Advanced Wound Care Marketing at ConvaTec where she led both the chronic and surgical marketing teams in a strategic go-to-market and digital transformation to increase customer engagement and has delivered market share growth and EBIT targets in an increasingly competitive space.
Cory has a unique and creative approach to the market and a deep passion for bringing innovative, disruptive technologies to patients in need.
VP HEALTHCARE SYSTEMS & TRAINING
+1 215-208-5713 email@example.com
Daniel has over 15+ years of wound care leadership experience in sales, marketing, and strategic accounts. His team has been responsible for a wide portfolio of wound care technologies including regenerative tissue, negative pressure wound therapy, remote patient monitoring, advanced wound dressings, and debridement solutions.
Daniel has successfully launched new divisions and wound care technologies while working for a start-up organization and most recently Smith & Nephew, a global leader in the medical device industry.
Kevin comes to Reapplix with 27 years of Wound Care experience, building and merging sales forces in the Acute Market, Wound Care Centers, Operating Room and Long-Term Care settings. He was part of many transformational changes such as launching Enzymatic Debriding Agents into the Acute and Long-term care markets, building, and launching the Oasis skin substitute sales force into the operating room and commercializing Leaf patient monitoring system, a digital platform to reduce the incidence of pressure ulcers. In addition, to sales force leadership, he created sales force access, building both a National Accounts Department and a Strategic Accounts Department to influence a C-Suite top-down strategy.